{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:38:26Z","timestamp":1793140706881,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Extrahepatic disease progression limits clinical efficacy of Yttrium-90 (<jats:sup>90<\/jats:sup>Y) radioembolization (TARE) for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Trifluridine and tipiracil (TAS-102) has overall survival benefit for patients with refractory mCRC and may be a radiosensitizer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sequential lobar TARE using <jats:sup>90<\/jats:sup>Y resin microspheres in combination with TAS-102 in 28-day\u2009cycles were used to treat adult patients with bilobar liver-dominant chemo-refractory mCRC according to 3\u2009+\u20093 dose escalation design with a 12-patient dose expansion cohort. Study objectives were to establish safety and determine maximum tolerated dose (MTD) of TAS-102 in combination with TARE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 21 patients (14 women, 7 men) with median age of 60\u2009years were enrolled. No dose limiting toxicities were observed. Treatment related severe adverse events included cytopenias (10 patients, 48%) and radioembolization-induced liver disease (2 patients, 10%). Disease control rate in the liver lobes treated with TARE was 100%. Best observed radiographic responses were partial response for 4 patients (19%) and stable disease for 12 patients (57%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The combination of TAS-102 and TARE for patients with liver-dominant mCRC is safe and consistently achieves disease control within the liver.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02602327?term=02602327&amp;draw=2&amp;rank=1\">NCT02602327<\/jats:ext-link> (first posted 11\/11\/2015).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10401-0","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T22:02:24Z","timestamp":1670968944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases"],"prefix":"10.1186","volume":"22","author":[{"given":"Nicholas","family":"Fidelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe E.","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alexandra","family":"Milloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Van Loon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"10401_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s11605-006-0061-3","volume":"11","author":"TM Pawlik","year":"2007","unstructured":"Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057\u201377.","journal-title":"J Gastrointest Surg"},{"key":"10401_CR2","volume":"16","author":"A Al-Asfoor","year":"2008","unstructured":"Al-Asfoor A, Feorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Chochrane Database Syst Rev. 2008;16:CD006039.","journal-title":"Chochrane Database Syst Rev"},{"key":"10401_CR3","first-page":"871","volume":"24","author":"HA Zeissman","year":"1983","unstructured":"Zeissman HA, Thrall JH, Gyves JW, Ensminger WD, Niederhuber JE, Tuscan M, et al. Quantitative hepatic arterial perfusion scintigraphy and starch microspheres in cancer chemotherapy. J Nucl Med. 1983;24:871\u20135.","journal-title":"J Nucl Med"},{"key":"10401_CR4","first-page":"178","volume":"5","author":"A Kennedy","year":"2014","unstructured":"Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5:178\u201389.","journal-title":"J Gastrointest Oncol"},{"key":"10401_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/sj.bjc.6605770","volume":"103","author":"M Cosimelli","year":"2010","unstructured":"Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, et al. Multi-Centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy-refractory colorectal liver metastases. Br J Cancer. 2010;103:324\u201331.","journal-title":"Br J Cancer"},{"key":"10401_CR6","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","volume":"28","author":"A Hendlisz","year":"2010","unstructured":"Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687\u201394.","journal-title":"J Clin Oncol"},{"key":"10401_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clcc.2013.11.010","volume":"13","author":"CT Sofocleous","year":"2014","unstructured":"Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014;13:27\u201336.","journal-title":"Clin Colorectal Cancer"},{"key":"10401_CR8","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1200\/JCO.21.01839","volume":"39","author":"MF Mulcahy","year":"2021","unstructured":"Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, et al. EPOCH Investigators. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol. 2021;39:3897\u2013907.","journal-title":"J Clin Oncol"},{"key":"10401_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","volume":"34","author":"GA Van Hazel","year":"2016","unstructured":"Van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34:1723\u201331.","journal-title":"J Clin Oncol"},{"key":"10401_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.21037\/jgo.2016.08.04","volume":"7","author":"N Fidelman","year":"2016","unstructured":"Fidelman N, Kerlan RK Jr, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, et al. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016;7:860\u201374.","journal-title":"J Gastrointest Oncol"},{"key":"10401_CR11","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Cutsem EV, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metasatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","journal-title":"N Engl J Med"},{"key":"10401_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2020.08.038","volume":"493","author":"K Rothkamm","year":"2020","unstructured":"Rothkamm K, Christianesen S, Rieckmann T, Horn M, Frenzel T, Brinker A, et al. Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine\/tipiracil and X-rays. Cancer Lett. 2020;493:179\u201388.","journal-title":"Cancer Lett"},{"key":"10401_CR13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/hep.26191","volume":"57","author":"B Gil-Alzugaray","year":"2013","unstructured":"Gil-Alzugaray B, An C, Anarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013;57:1078\u201387.","journal-title":"Hepatology"},{"key":"10401_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00270-007-9064-z","volume":"30","author":"RJ Lewandowski","year":"2007","unstructured":"Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571\u201392.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"suppl 2","key":"10401_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","volume":"13","author":"R Pazdur","year":"2008","unstructured":"Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13(suppl 2):19\u201321.","journal-title":"Oncologist"},{"key":"10401_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randimised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13:993\u20131001.","journal-title":"Lancet Oncol"},{"key":"10401_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, Moller S, Zitnjak D, Krogh M, Petersen LN, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomized, phase 2 trial. Lancet Oncol. 2020;21:412\u201320.","journal-title":"Lancet Oncol"},{"key":"10401_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s00270-013-0547-9","volume":"26","author":"MG Lam","year":"2013","unstructured":"Lam MG, Louie JD, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;26:1320\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10401_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/bjc.2014.344","volume":"111","author":"SJ Cohen","year":"2014","unstructured":"Cohen SJ, Konski AA, Putnam S, Ball DS, Meyer JE, Yu JQ, et al. Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-spheres) in patients with advanced cancer. Br J Cancer. 2014;111:265\u201371.","journal-title":"Br J Cancer"},{"key":"10401_CR20","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","volume":"46","author":"R Salem","year":"2019","unstructured":"Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46:1695\u2013704.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10401_CR21","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.jvir.2018.07.006","volume":"29","author":"C Allimant","year":"2018","unstructured":"Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, et al. Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after Yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:1662\u201370.","journal-title":"J Vasc Interv Radiol"},{"key":"10401_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","volume":"48","author":"H Levillain","year":"2021","unstructured":"Levillain H, Bagni O, Deroose CM, Dieudonn\u00e9 A, Gnesin S, Grosser OS, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48:1570\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10401_CR23","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10401_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1055\/s-0031-1280652","volume":"28","author":"DB Brown","year":"2011","unstructured":"Brown DB. Hepatic artery dissection in a patient on bevacizumab resulting in pseudoaneurysm formation. Semin Intervent Radiol. 2011;28:142\u20136.","journal-title":"Semin Intervent Radiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10401-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10401-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10401-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T22:03:09Z","timestamp":1670968989000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10401-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10401"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10401-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"1 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was reviewed and approved by the Institutional Review Board (IRB) at University of California San Francisco (CC#16452). The study was performed in accordance with the Declaration of Helsinki. All patient signed written informed consent after being advised of risks, benefits, and alternatives of study treatments and trial participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was supported by an independent research grant from SIRTEX Medical, Inc. to University of California San Francisco (Nicholas Fidelman, Principal Investigator). None of the other authors have any relevant conflict of interest disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1307"}}